Clinical trial
A Prospective Trial of Anti-TNF-Alpha Chimeric Monoclonal Antibody (Infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity
NCT00636142 is registered in ClinicalTrials.gov with Medical University of Graz as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Trial of Anti-TNF-Alpha Chimeric Monoclonal Antibody (Infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity
- Lead sponsor
- Medical University of Graz
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- September 30, 2005
- Completion date
- September 30, 2007
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.